Bisantrene

Modify Date: 2024-01-02 09:58:06

Bisantrene Structure
Bisantrene structure
Common Name Bisantrene
CAS Number 78186-34-2 Molecular Weight 398.46400
Density 1.41g/cm3 Boiling Point 646.3ºC at 760 mmHg
Molecular Formula C22H22N8 Melting Point N/A
MSDS N/A Flash Point 344.7ºC
Symbol GHS07 GHS09
GHS07, GHS09
Signal Word Warning

 Use of Bisantrene


Bisantrene is a highly effective antitumor drug, targets eukaryotic type II topoisomerases.

 Names

Name Bisantrene
Synonym More Synonyms

 Bisantrene Biological Activity

Description Bisantrene is a highly effective antitumor drug, targets eukaryotic type II topoisomerases.
Related Catalog
Target

Topoisomerase II

In Vivo Bisantrene shows an outstanding ability to form a complex with DNA. Bisantrene exhibits the most effective binding (even neglecting electrostatic contacts), followed by the 9-substituted compounds and finally by 1-IHA. Bisantrene congeners retained a remarkable capacity for binding to the single-stranded structure. In comparison with the Ki values found for double-stranded DNA, 9-IHA shows a 2-fold increase, 1-IHA maintains the same values, and aza-9-IHA exhibits a modest reduction. On the other hand, Bisantrene, although undergoing a 6-fold reduction in Ki, still exhibits an affinity constant of the order of 106 M-1. Bisantrene promots DNase I cleavage at oligopurine-oligopyrimidine tracts; conversely, it slightly reduces the cleavage activity at alternating purine-pyrimidine sequences[1]. Bisantrene is an active new drug in the treatment of metastatic breast cancer. Bisantrene is an inhibitor of [3H]uridine incorporation into RNA and [3H]thymidine incorporation into DNA[2].
Kinase Assay Measurements are carried out at 25°C in ETN buffer (1 mM EDTA, 10 mM Tris, pH 7.0, with NaCl to obtain the desired ionic strength). Binding is monitored spectrophotometrically or fluorometrically, in the ligand absorption or emission region, respectively, after addition of scalar amounts of DNA to a freshly prepared drug solution. To avoid large systematic inaccuracies resulting from experimental errors in extinction coefficients or fluorescence quantum yield, the range of bound drug fractions is 0.15-0.85. Data are evaluated. Spectroscopic measurements are made with a Perkin-Elmer Lambda 5 apparatus and a MPF66 fluorometer, both equipped with a Haake F3-C thermostat[1].
References

[1]. Sissi C, et al. DNA-binding preferences of Bisantrene analogues: relevance to the sequence specificity of drug-mediated topoisomerase II poisoning. Mol Pharmacol. 1998 Dec;54(6):1036-45.

[2]. Yap HY, et al. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res. 1983 Mar;43(3):1402-4.

 Chemical & Physical Properties

Density 1.41g/cm3
Boiling Point 646.3ºC at 760 mmHg
Molecular Formula C22H22N8
Molecular Weight 398.46400
Flash Point 344.7ºC
Exact Mass 398.19700
PSA 97.56000
LogP 2.06900
Index of Refraction 1.757
Water Solubility deionized water: soluble8mg/mL

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
CA9645000
CHEMICAL NAME :
9,10-Anthracenedicarboxaldehyde, bis((4,5-dihydro-1H-imidazol-2-yl)hydrazone)-
CAS REGISTRY NUMBER :
78186-34-2
LAST UPDATED :
199612
DATA ITEMS CITED :
1
MOLECULAR FORMULA :
C22-H22-N8

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
245 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 46,2703,1986

 Safety Information

Symbol GHS07 GHS09
GHS07, GHS09
Signal Word Warning
Hazard Statements H302-H400
Precautionary Statements P273
Hazard Codes Xn;N
Risk Phrases R22;R50/53
Safety Phrases S60;S61
RIDADR UN 2811 6.1/PG 3
HS Code 2933290090

 Customs

HS Code 2933290090
Summary 2933290090. other compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Articles24

More Articles
In vitro effects of bisantrene on fresh clonogenic leukemia cells: a preliminary study on 15 cases.

Haematologica 75(6) , 527-31, (1990)

In vitro clonogenic assays may be useful for determining the sensitivity of leukemic cells to chemotherapeutic agents. We evaluated the antileukemic effect of Bisantrene (an anthracene derivative now ...

Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.

Med. Pediatr. Oncol. 19(2) , 126-8, (1991)

Sixteen patients with metastatic melanoma entered this phase II study of the efficacy of monthly cycles of Bisantrene. Toxicity was characterized by leukopenia, resulting in the hospitalization of one...

Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.

Clin. Cancer Res. 2(6) , 973-80, (1996)

In this work, we demonstrate a protective effect conferred by the human multidrug resistance gene (MDR1) to populations of the murine hematopoietic system against the toxic effects of bisantrene, a no...

 Synonyms

9,10-Anthracenedicarbaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]
MFCD01743164
9,10-Anthracenedicarboxaldehyde bis(2-imidazolin-2-ylhydrazone)
Zantrene
ADAH
BISANTRENE HCL
anthracene-9,10-dicarbaldehyde bis-imidazolidin-2-ylidenehydrazone
Orange Crush